[go: up one dir, main page]

DE69733321D1 - Olanzapine zur behandlung von drogenmissbrauch - Google Patents

Olanzapine zur behandlung von drogenmissbrauch

Info

Publication number
DE69733321D1
DE69733321D1 DE69733321T DE69733321T DE69733321D1 DE 69733321 D1 DE69733321 D1 DE 69733321D1 DE 69733321 T DE69733321 T DE 69733321T DE 69733321 T DE69733321 T DE 69733321T DE 69733321 D1 DE69733321 D1 DE 69733321D1
Authority
DE
Germany
Prior art keywords
olanzapine
treatment
drug abuse
administering
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69733321T
Other languages
German (de)
English (en)
Inventor
M Beasley
Kurt Rasmussen
D Tollefson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606615.4A external-priority patent/GB9606615D0/en
Priority claimed from GBGB9606617.0A external-priority patent/GB9606617D0/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE69733321D1 publication Critical patent/DE69733321D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Disintegrating Or Milling (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Steroid Compounds (AREA)
DE69733321T 1996-03-11 1997-03-10 Olanzapine zur behandlung von drogenmissbrauch Expired - Lifetime DE69733321D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1316096P 1996-03-11 1996-03-11
US1316196P 1996-03-11 1996-03-11
GBGB9606615.4A GB9606615D0 (en) 1996-03-29 1996-03-29 Method for treating alcohol addiction
GBGB9606617.0A GB9606617D0 (en) 1996-03-29 1996-03-29 Method for treating substance abuse
PCT/US1997/003404 WO1997033586A1 (en) 1996-03-11 1997-03-10 Method for treating substance abuse

Publications (1)

Publication Number Publication Date
DE69733321D1 true DE69733321D1 (de) 2005-06-23

Family

ID=27451428

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69733321T Expired - Lifetime DE69733321D1 (de) 1996-03-11 1997-03-10 Olanzapine zur behandlung von drogenmissbrauch

Country Status (15)

Country Link
EP (1) EP1007050B1 (xx)
JP (1) JP2000517287A (xx)
KR (1) KR19990087714A (xx)
CN (1) CN1213308A (xx)
AT (1) ATE295731T1 (xx)
BR (1) BR9708037A (xx)
CA (1) CA2248738A1 (xx)
CZ (1) CZ290398A3 (xx)
DE (1) DE69733321D1 (xx)
IL (1) IL126158A0 (xx)
NO (1) NO984196L (xx)
NZ (1) NZ331845A (xx)
PL (1) PL328924A1 (xx)
TR (1) TR199801801T2 (xx)
WO (1) WO1997033586A1 (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2211205T3 (es) * 1998-11-23 2004-07-01 Sepracor Inc. Composiciones farmaceuticas que contienen olanzapina-n-oxido.
US6174882B1 (en) 1998-11-23 2001-01-16 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
JP2002530341A (ja) 1998-11-23 2002-09-17 セプラコール， インク． デスメチルオランザピン組成物及び方法
EP1349556A2 (en) * 2001-01-12 2003-10-08 Innovation Ventures, LLC Activated charcoal based composition and method for reducing hangover symptoms associated with the consumption of alcohol containing beverages
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5605911A (en) * 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US5696115A (en) * 1995-04-21 1997-12-09 Eli Lilly And Company Method for treating nicotine withdrawal

Also Published As

Publication number Publication date
ATE295731T1 (de) 2005-06-15
EP1007050B1 (en) 2005-05-18
PL328924A1 (en) 1999-03-01
CA2248738A1 (en) 1997-09-18
NO984196L (no) 1998-11-03
NZ331845A (en) 2000-09-29
AU725940B2 (en) 2000-10-26
JP2000517287A (ja) 2000-12-26
KR19990087714A (ko) 1999-12-27
WO1997033586A1 (en) 1997-09-18
BR9708037A (pt) 1999-07-27
EP1007050A1 (en) 2000-06-14
EP1007050A4 (en) 2000-06-14
AU2067297A (en) 1997-10-01
CZ290398A3 (cs) 1999-10-13
NO984196D0 (no) 1998-09-11
TR199801801T2 (xx) 1998-12-21
CN1213308A (zh) 1999-04-07
IL126158A0 (en) 1999-05-09

Similar Documents

Publication Publication Date Title
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
ATE207352T1 (de) Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen
ATE510542T1 (de) Noribogain zur behandlung von schmerzen und drogenabhängigkeit
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
ATE222109T1 (de) Kombiniertes therapeutisches verfahren zur behandlung von hyperproliferativen krankheiten
YU42298A (sh) Upotreba olanzapina za pripremanje leka korisnog kod akutnog bola
DE69829217D1 (de) Vorrichtung zur therapeutischen behandlung von blutgefässen
ATA901396A (de) Verwendung von melatonin zur behandlung von an medikamentensucht leidenden patienten
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
NO984198L (no) FremgangsmÕte for behandling av aggresjon
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
EA199800820A1 (ru) Способ лечения злоупотребления лекарственными средствами
DE69800906D1 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
ATE337783T1 (de) Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen
RU97110384A (ru) Способ лечения вибрационной болезни
DE69430807D1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen
EA199800818A1 (ru) Способ лечения бессонницы
YU40198A (sh) Postupak za tretiranje zavisnosti od supstance
ATA157396A (de) Pharmazeutisches präparat zur behandlung von blutgerinnungsstörungen
ATA17797A (de) Pharmazeutisches präparat zur behandlung von blutgerinnungsstörungen
ATA51896A (de) Pharmazeutisches präparat zur behandlung von blutgerinnungsstörungen

Legal Events

Date Code Title Description
8332 No legal effect for de